Clinical Trials Logo

Giant Cell Arteritis clinical trials

View clinical trials related to Giant Cell Arteritis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05681676 Completed - Clinical trials for Polymyalgia Rheumatica

Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients

Start date: March 1, 2012
Phase:
Study type: Observational

Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and rheumatoid arthritis (RA). The proteomic profile of PMR patients remains uncharacterized and biomarker studies very limited. The primary aim of this study was to thoroughly investigate the lymphocyte expression of melanocortin receptors, and the serum proteome during glucocorticoid treatment of PMR with a focus on acute-phase reactions, the complement system, and pro-inflammatory cytokines.

NCT ID: NCT05604482 Completed - Diagnoses Disease Clinical Trials

CXCR4-PET/CT for Diagnosing Giant Cell Arteritis

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy. For large-vessel GCA (LV-GCA) involving the aorta and its branches, FDG-PET/CT is the standard in imaging for diagnosis and is recommended by the guidelines. However, this only indirectly visualizes inflammation through vessel wall uptake of glucose. A new PET tracer, 68Ga-pentixafor, is used to visualize the chemokine receptor CXCR4. This receptor is expressed by cells of the immune system. In the context of inflammatory processes, upregulation of CXCL12, the ligand of CXCR4, occurs in affected tissues. The chemotactic effect of this ligand leads to the immigration of CXCR4-positive inflammatory cells into the inflamed area, which can be visualized by PET using the CXCR4-specific tracer 68Ga-Pentixafor. The value of CXCR4-PET should therefore be tested in the context of LV-GCA. This study tests the benefit of CXCR4 in therapy-naïve patients with suspected LV-GCA. For this purpose, patients will receive a FDG-PET and a CXCR4-PET for direct comparison. This is an imaging-only study. Therapy will not be affected by the study. The study is single-arm and not blinded.

NCT ID: NCT05246540 Completed - Clinical trials for Giant Cell Arteritis

Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis

Cervico-TEP et
Start date: January 1, 2020
Phase:
Study type: Observational

Giant cell arteritis (GCA) is the most common vasculitis in adults. The diagnosis of GCA is evoked by the association of clinical signs and biological anomalies (inflammatory syndrome) in patients over 50 years of age. On the other hand, starting a treatment implies being certain of the diagnosis which requires performing a temporal artery biopsy under local anesthesia. This examination is therefore an invasive procedure for patients whose sensitivity is not optimal. This is why imaging techniques (echo-Doppler or MRI of the temporal arteries) have been developed to look for signs of vasculitis without the need to perform a biopsy. However, these examinations lack sensitivity (=falsely concluding the absence of GCA) and specificity (=falsely concluding the presence of GCA). Recently, advances in imaging, and in particular positron emission tomography (PET), have made it possible to visualize the cephalic arteries, including the temporal artery. The aim of this study is therefore to evaluate the sensitivity and specificity of PET of the cephalic arteries for the diagnosis of GCA and to compare them with those of echo-Doppler and MRI of the temporal arteries.

NCT ID: NCT04885829 Completed - Clinical trials for Rheumatoid Arthritis

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Start date: May 31, 2021
Phase: Phase 1
Study type: Interventional

A single dose, two period trial where participants will be given either of 3 Tocilizumab product on Day 1 during period 1 and either one of the remaining 2 Tocilizumab products on Day 1 period 2. There will be at least 6 weeks (42 days) of wash out between subsequent two period dosing. The maximum flexibility allowed between subsequent periods will be up to 9 weeks (63 days). Names of the 3 tocilizumab products are DRL_TC, RP and RMP. So if a participant receives DRL_TC on Day 1 Period 1 then he/she will either receive RP/RMP on Day 1 Period 2.

NCT ID: NCT04799262 Completed - Safety Issues Clinical Trials

Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Glucocorticoids are the cornerstone treatment for polymyalgia rheumatica but induce adverse events. The efficacy of the candidate drug Tofacitinib has not yet been demonstrated in controlled studies. The aim of the study is to investigate the efficacy and safety of Tofacitinib as a glucocorticoid sparing agent in patients with polymyalgia rheumatica.

NCT ID: NCT04727879 Completed - Clinical trials for Polymyalgia Rheumatica

Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's Biopsies

BAOBAB
Start date: April 7, 2021
Phase: N/A
Study type: Interventional

The work carried out at the Brest University Hospital on serum immunological changes in patients with polymyalgia rheumatica (PMR) (based on clinical protocols TENOR, SEMAPHORE, THEN) made it possible to describe the changes in the distribution of lymphocyte subpopulations and cytokine levels during PPR, before and then under treatment compared to controls. However, in systemic autoimmune or inflammatory pathologies, serum immunological mechanisms are rarely a reflection of intra-tissue mechanisms. In the specific case of PMR, there are few data concerning muscular or joint immunological modifications. The investigators now wish to study the immunological modifications occurring at the tissue sites of interest, in particular in the shoulder bursae

NCT ID: NCT04554290 Completed - Clinical trials for Giant Cell Arteritis

Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy

Start date: August 1, 2020
Phase:
Study type: Observational

Temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. However, other diagnoses might be associated with abnormal temporal artery biopsy. The purpose of this study is to describe the frequency of giant cell arteritis differential diagnoses with positive temporal artery biopsy.

NCT ID: NCT04239521 Completed - Asthma Clinical Trials

The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata

Start date: October 1, 2020
Phase:
Study type: Observational

This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.

NCT ID: NCT04204876 Completed - Clinical trials for Giant Cell Arteritis

Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course

Start date: May 28, 2020
Phase:
Study type: Observational

Longitudinal imaging in patients with large vessel vasculitis to predict further disease course

NCT ID: NCT04204512 Completed - Clinical trials for Giant Cell Arteritis

Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis

ECHORTON
Start date: December 17, 2019
Phase:
Study type: Observational

Evaluation of the structural features of temporal arteritis using two frequencies probes: 18 and 22Mhz.